Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 1212

1.

Treatment of Pediatric Glioblastoma with Combination Olaparib and Temozolomide Demonstrates 2-Year Durable Response.

Valiakhmetova A, Gorelyshev S, Konovalov A, Trunin Y, Savateev A, Kram DE, Severson E, Hemmerich A, Edgerly C, Duncan D, Britt N, Huang RSP, Elvin J, Miller V, Ross JS, Gay L, McCorkle J, Rankin A, Erlich RL, Chudnovsky Y, Ramkissoon SH.

Oncologist. 2019 Oct 16. pii: theoncologist.2019-0603. doi: 10.1634/theoncologist.2019-0603. [Epub ahead of print] Review.

PMID:
31619547
2.

Use of Mechanical Cardiopulmonary Resuscitation Devices for Out-of-Hospital Cardiac Arrest, 2010-2016.

Kahn PA, Dhruva SS, Rhee TG, Ross JS.

JAMA Netw Open. 2019 Oct 2;2(10):e1913298. doi: 10.1001/jamanetworkopen.2019.13298.

PMID:
31617923
3.

Brief Report: Calculating the Tumor Nuclei Content for Comprehensive Cancer Panel Testing.

Mikubo M, Seto K, Kitamura A, Nakaguro M, Hattori Y, Nagako M, Miyazaki T, Watanabe K, Murakami H, Tsukamoto T, Yamada T, Fujita S, Masago K, Ramkissoon S, Ross JS, Elvin J, Yatabe Y.

J Thorac Oncol. 2019 Oct 9. pii: S1556-0864(19)33409-4. doi: 10.1016/j.jtho.2019.09.081. [Epub ahead of print]

PMID:
31605798
4.

The Pan-Cancer Landscape of Coamplification of the Tyrosine Kinases KIT, KDR, and PDGFRA.

Disel U, Madison R, Abhishek K, Chung JH, Trabucco SE, Matos AO, Frampton GM, Albacker LA, Reddy V, Karadurmus N, Benson A, Webster J, Paydas S, Cabanillas R, Nangia C, Ozturk MA, Millis SZ, Pal SK, Wilky B, Sokol ES, Gay LM, Soman S, Ganesan S, Janeway K, Stephens PJ, Zhu VW, Ou SI, Lovly CM, Gounder M, Schrock AB, Ross JS, Miller VA, Klempner SJ, Ali SM.

Oncologist. 2019 Oct 11. pii: theoncologist.2018-0528. doi: 10.1634/theoncologist.2018-0528. [Epub ahead of print]

PMID:
31604903
5.

Characteristics of Recent Generic Drug Approvals by the US Food and Drug Administration.

Jiao K, Gupta R, Fox E, Kesselheim A, Ross JS.

JAMA Netw Open. 2019 Oct 2;2(10):e1913029. doi: 10.1001/jamanetworkopen.2019.13029. No abstract available.

PMID:
31603482
6.

Home Health Care After Skilled Nursing Facility Discharge Following Heart Failure Hospitalization.

Weerahandi H, Bao H, Herrin J, Dharmarajan K, Ross JS, Jones S, Horwitz LI.

J Am Geriatr Soc. 2019 Oct 11. doi: 10.1111/jgs.16179. [Epub ahead of print]

PMID:
31603248
7.

Genomic profiling of cell-free circulating tumor DNA in patients with colorectal cancer and its fidelity to the genomics of the tumor biopsy.

Li G, Pavlick D, Chung JH, Bauer T, Tan BA, Peguero J, Ward P, Kallab A, Bufill J, Hoffman A, Sadiq A, Edenfield J, He J, Cooke M, Hughes J, Forcier B, Nahas M, Stephens P, Ali SM, Schrock AB, Ross JS, Miller VA, Gregg JP.

J Gastrointest Oncol. 2019 Oct;10(5):831-840. doi: 10.21037/jgo.2019.05.05.

8.

Feasibility of Using Real-World Data to Replicate Clinical Trial Evidence.

Bartlett VL, Dhruva SS, Shah ND, Ryan P, Ross JS.

JAMA Netw Open. 2019 Oct 2;2(10):e1912869. doi: 10.1001/jamanetworkopen.2019.12869.

PMID:
31596493
9.

Evolution of Medicare Formulary Coverage Changes for Antithrombotic Therapies After Guideline Updates.

Dayoub EJ, Ross JS, Shah ND, Dhruva SS.

Circulation. 2019 Oct;140(14):1227-1230. doi: 10.1161/CIRCULATIONAHA.119.040580. Epub 2019 Sep 30. No abstract available.

PMID:
31567008
10.

Evolution of the American College of Cardiology and American Heart Association Cardiology Clinical Practice Guidelines: A 10-Year Assessment.

DuBose-Briski V, Yao X, Dunlay SM, Dhruva SS, Ross JS, Shah ND, Noseworthy PA.

J Am Heart Assoc. 2019 Oct;8(19):e012065. doi: 10.1161/JAHA.119.012065. Epub 2019 Sep 28.

11.

Biomarkers as Surrogate Endpoints: Ongoing Opportunities for Validation.

Zhang AD, Ross JS.

J Law Med Ethics. 2019 Sep;47(3):393-395. doi: 10.1177/1073110519876170.

PMID:
31560627
12.

Genetic hallmarks of recurrent/metastatic adenoid cystic carcinoma.

Ho AS, Ochoa A, Jayakumaran G, Zehir A, Valero Mayor C, Tepe J, Makarov V, Dalin MG, He J, Bailey M, Montesion M, Ross JS, Miller VA, Chan L, Ganly I, Dogan S, Katabi N, Tsipouras P, Ha P, Agrawal N, Solit DB, Futreal PA, El Naggar AK, Reis-Filho JS, Weigelt B, Ho AL, Schultz N, Chan TA, Morris LG.

J Clin Invest. 2019 Oct 1;129(10):4276-4289. doi: 10.1172/JCI128227.

13.

Evidence Supporting US Food and Drug Administration Drug Safety Communications.

Ross JS.

JAMA Intern Med. 2019 Sep 3. doi: 10.1001/jamainternmed.2019.3065. [Epub ahead of print] No abstract available.

PMID:
31479098
14.

A Novel Next-Generation Sequencing Approach to Detecting Microsatellite Instability and Pan-Tumor Characterization of 1000 Microsatellite Instability-High Cases in 67,000 Patient Samples.

Trabucco SE, Gowen K, Maund SL, Sanford E, Fabrizio DA, Hall MJ, Yakirevich E, Gregg JP, Stephens PJ, Frampton GM, Hegde PS, Miller VA, Ross JS, Hartmaier RJ, Huang SA, Sun JX.

J Mol Diagn. 2019 Aug 22. pii: S1525-1578(19)30358-7. doi: 10.1016/j.jmoldx.2019.06.011. [Epub ahead of print]

15.

Comprehensive characterization of RAS mutations in colon and rectal cancers in old and young patients.

Serebriiskii IG, Connelly C, Frampton G, Newberg J, Cooke M, Miller V, Ali S, Ross JS, Handorf E, Arora S, Lieu C, Golemis EA, Meyer JE.

Nat Commun. 2019 Aug 19;10(1):3722. doi: 10.1038/s41467-019-11530-0.

16.

Adoption of New Glucose-Lowering Medications in the U.S.-The Case of SGLT2 Inhibitors: Nationwide Cohort Study.

McCoy RG, Dykhoff HJ, Sangaralingham L, Ross JS, Karaca-Mandic P, Montori VM, Shah ND.

Diabetes Technol Ther. 2019 Oct 9. doi: 10.1089/dia.2019.0213. [Epub ahead of print]

PMID:
31418588
17.

Comprehensive Genomic Profiling of Adult Renal Sarcomas Provides Insight into Disease Biology and Opportunities for Targeted Therapies.

Yakirevich E, Madison R, Fridman E, Mangray S, Carneiro BA, Lu S, Cooke M, Bratslavsky G, Webster J, Ross JS, Ali SM.

Eur Urol Oncol. 2019 Apr 22. pii: S2588-9311(19)30044-6. doi: 10.1016/j.euo.2019.04.002. [Epub ahead of print]

PMID:
31412008
18.

Medicare Part D Spending on Single-Enantiomer Drugs Versus Their Racemic Precursors.

Egilman AC, Zhang AD, Wallach JD, Ross JS.

Ann Intern Med. 2019 Aug 13. doi: 10.7326/M19-1085. [Epub ahead of print] No abstract available.

PMID:
31404926
19.

MET Genomic Alterations in Head and Neck Squamous Cell Carcinoma (HNSCC): Rapid Response to Crizotinib in a Patient with HNSCC with a Novel MET R1004G Mutation.

Chu LP, Franck D, Parachoniak CA, Gregg JP, Moore MG, Farwell DG, Rao S, Heilmann AM, Erlich RL, Ross JS, Miller VA, Ali S, Riess JW.

Oncologist. 2019 Oct;24(10):1305-1308. doi: 10.1634/theoncologist.2019-0230. Epub 2019 Aug 7.

PMID:
31391294
20.

Rates of Physician Coprescribing of Opioids and Benzodiazepines After the Release of the Centers for Disease Control and Prevention Guidelines in 2016.

Jeffery MM, Hooten WM, Jena AB, Ross JS, Shah ND, Karaca-Mandic P.

JAMA Netw Open. 2019 Aug 2;2(8):e198325. doi: 10.1001/jamanetworkopen.2019.8325.

21.

Improving the Prognostic Ability for Personalized Therapeutic Approaches in Nonseminomatous Germ Cell Tumors.

Necchi A, Ross JS, Spiess PE.

J Clin Oncol. 2019 Sep 10;37(26):2314-2316. doi: 10.1200/JCO.19.01672. Epub 2019 Jul 30. No abstract available.

PMID:
31361537
22.

Medicare Spending on Drugs and Biologics Not Recommended for Coverage by International Health Technology Assessment Agencies.

Egilman AC, Wallach JD, Dhruva SS, Gonsalves GS, Ross JS.

J Gen Intern Med. 2019 Jul 16. doi: 10.1007/s11606-019-05149-6. [Epub ahead of print] No abstract available.

PMID:
31313117
23.

The Bleeding Edge: Documenting Innovation and Injury in the Medical Device Industry.

Pendyal A, Ross JS.

JAMA. 2019 Jul 16;322(3):190-192. doi: 10.1001/jama.2019.8147. No abstract available.

PMID:
31310276
24.

Association Between Food and Drug Administration Advisory Committee Recommendations and Agency Actions, 2008-2015.

Zhang AD, Schwartz JL, Ross JS.

Milbank Q. 2019 Sep;97(3):796-819. doi: 10.1111/1468-0009.12403. Epub 2019 Jul 14.

PMID:
31304643
25.

Pan-Cancer Analysis of CDK12 Loss-of-Function Alterations and Their Association with the Focal Tandem-Duplicator Phenotype.

Sokol ES, Pavlick D, Frampton GM, Ross JS, Miller VA, Ali SM, Lotan TL, Pardoll DM, Chung JH, Antonarakis ES.

Oncologist. 2019 Jul 10. pii: theoncologist.2019-0214. doi: 10.1634/theoncologist.2019-0214. [Epub ahead of print]

PMID:
31292271
27.

Clinical Trial Evidence for the Real World.

Ross JS, Covinsky K.

JAMA Intern Med. 2019 Jul 8. doi: 10.1001/jamainternmed.2019.1500. [Epub ahead of print] No abstract available.

PMID:
31282933
28.

Association Between Industry Payments to Physicians and Gabapentinoid Prescribing.

Rhee TG, Ross JS.

JAMA Intern Med. 2019 Jul 8. doi: 10.1001/jamainternmed.2019.1082. [Epub ahead of print] No abstract available.

PMID:
31282922
29.

Prevalence of established and emerging biomarkers of immune checkpoint inhibitor response in advanced hepatocellular carcinoma.

Ang C, Klempner SJ, Ali SM, Madison R, Ross JS, Severson EA, Fabrizio D, Goodman A, Kurzrock R, Suh J, Millis SZ.

Oncotarget. 2019 Jun 18;10(40):4018-4025. doi: 10.18632/oncotarget.26998. eCollection 2019 Jun 18.

30.

FGFR2-Altered Gastroesophageal Adenocarcinomas Are an Uncommon Clinicopathologic Entity with a Distinct Genomic Landscape.

Klempner SJ, Madison R, Pujara V, Ross JS, Miller VA, Ali SM, Schrock AB, Kim ST, Maron SB, Dayyani F, Catenacci DVT, Lee J, Chao J.

Oncologist. 2019 Jun 27. pii: theoncologist.2019-0121. doi: 10.1634/theoncologist.2019-0121. [Epub ahead of print]

PMID:
31249137
31.

Clinical and Immunological Implications of Frameshift Mutations in Lung Cancer.

Chae YK, Viveiros P, Lopes G, Sukhadia B, Sheikh MM, Saravia D, Florou V, Sokol ES, Frampton GM, Chalmers ZR, Ali SM, Ross JS, Chang S, Wang S, Chiec L, Rahbari A, Mohindra N, Villaflor V, Shin SH, Oh M, Anker J, Park LC, Wang V, Chuang J, Park W.

J Thorac Oncol. 2019 Oct;14(10):1807-1817. doi: 10.1016/j.jtho.2019.06.016. Epub 2019 Jun 22.

PMID:
31238177
32.

Prospective Comprehensive Genomic Profiling of Primary and Metastatic Prostate Tumors.

Chung JH, Dewal N, Sokol E, Mathew P, Whitehead R, Millis SZ, Frampton GM, Bratslavsky G, Pal SK, Lee RJ, Necchi A, Gregg JP, Lara P Jr, Antonarakis ES, Miller VA, Ross JS, Ali SM, Agarwal N.

JCO Precis Oncol. 2019;3. doi: 10.1200/PO.18.00283. Epub 2019 May 10.

33.

Postmarketing commitments for novel drugs and biologics approved by the US Food and Drug Administration: a cross-sectional analysis.

Wallach JD, Luxkaranayagam AT, Dhruva SS, Miller JE, Ross JS.

BMC Med. 2019 Jun 17;17(1):117. doi: 10.1186/s12916-019-1344-3.

34.

SMARCA4 inactivation defines a subset of undifferentiated uterine sarcomas with rhabdoid and small cell features and germline mutation association.

Lin DI, Allen JM, Hecht JL, Killian JK, Ngo NT, Edgerly C, Severson EA, Ali SM, Erlich RL, Ramkissoon SH, Vergilio JA, Ross JS, Elvin JA.

Mod Pathol. 2019 Jun 12. doi: 10.1038/s41379-019-0303-z. [Epub ahead of print]

PMID:
31190001
35.

Noninferiority Designed Cardiovascular Trials in Highest-Impact Journals.

Bikdeli B, Welsh JW, Akram Y, Punnanithinont N, Lee I, Desai NR, Kaul S, Stone GW, Ross JS, Krumholz HM.

Circulation. 2019 Jul 30;140(5):379-389. doi: 10.1161/CIRCULATIONAHA.119.040214. Epub 2019 Jun 10.

PMID:
31177811
36.

Genomic Features of Metastatic Testicular Sex Cord Stromal Tumors.

Necchi A, Bratslavsky G, Shapiro O, Elvin JA, Vergilio JA, Killian JK, Ngo N, Ramkissoon S, Severson E, Hemmerich AC, Ali SM, Chung JH, Reddy P, Miller VA, Schrock AB, Gay LM, Ross JS, Jacob JM.

Eur Urol Focus. 2019 May 27. pii: S2405-4569(19)30149-X. doi: 10.1016/j.euf.2019.05.012. [Epub ahead of print]

PMID:
31147264
37.

Adverse Effects of Pharmacologic Treatments of Major Depression in Older Adults.

Sobieraj DM, Martinez BK, Hernandez AV, Coleman CI, Ross JS, Berg KM, Steffens DC, Baker WL.

J Am Geriatr Soc. 2019 Aug;67(8):1571-1581. doi: 10.1111/jgs.15966. Epub 2019 May 29.

PMID:
31140587
38.

Analysis of Postapproval Clinical Trials of Therapeutics Approved by the US Food and Drug Administration Without Clinical Postmarketing Requirements or Commitments.

Skydel JJ, Luxkaranayagam AT, Dhruva SS, Ross JS, Wallach JD.

JAMA Netw Open. 2019 May 3;2(5):e193410. doi: 10.1001/jamanetworkopen.2019.3410.

39.

Analysis of DNA Damage Response Gene Alterations and Tumor Mutational Burden Across 17,486 Tubular Gastrointestinal Carcinomas: Implications for Therapy.

Parikh AR, He Y, Hong TS, Corcoran RB, Clark JW, Ryan DP, Zou L, Ting DT, Catenacci DV, Chao J, Fakih M, Klempner SJ, Ross JS, Frampton GM, Miller VA, Ali SM, Schrock AB.

Oncologist. 2019 Oct;24(10):1340-1347. doi: 10.1634/theoncologist.2019-0034. Epub 2019 Apr 30.

PMID:
31040255
40.

Tumor mutational burden is predictive of response to immune checkpoint inhibitors in MSI-high metastatic colorectal cancer.

Schrock AB, Ouyang C, Sandhu J, Sokol E, Jin D, Ross JS, Miller VA, Lim D, Amanam I, Chao J, Catenacci D, Cho M, Braiteh F, Klempner SJ, Ali SM, Fakih M.

Ann Oncol. 2019 Jul 1;30(7):1096-1103. doi: 10.1093/annonc/mdz134.

PMID:
31038663
41.

Association of Pharmaceutical Manufacturer Payments to Physicians and Prescribing Dosage of Opioids.

Fleischman W, Agrawal S, Gross CP, Ross JS.

J Gen Intern Med. 2019 Jul;34(7):1074-1076. doi: 10.1007/s11606-019-04897-9. No abstract available.

PMID:
31011967
42.

Molecular profiling of cancer patients enables personalized combination therapy: the I-PREDICT study.

Sicklick JK, Kato S, Okamura R, Schwaederle M, Hahn ME, Williams CB, De P, Krie A, Piccioni DE, Miller VA, Ross JS, Benson A, Webster J, Stephens PJ, Lee JJ, Fanta PT, Lippman SM, Leyland-Jones B, Kurzrock R.

Nat Med. 2019 May;25(5):744-750. doi: 10.1038/s41591-019-0407-5. Epub 2019 Apr 22.

PMID:
31011206
43.

Adverse Effects of Pharmacologic Treatments of Major Depression in Older Adults [Internet].

Sobieraj DM, Baker WL, Martinez BK, Hernandez AV, Coleman CI, Ross JS, Berg KM, Steffens DC.

Rockville (MD): Agency for Healthcare Research and Quality (US); 2019 Mar.

44.

Risk of Readmission After Discharge From Skilled Nursing Facilities Following Heart Failure Hospitalization: A Retrospective Cohort Study.

Weerahandi H, Li L, Bao H, Herrin J, Dharmarajan K, Ross JS, Kim KL, Jones S, Horwitz LI.

J Am Med Dir Assoc. 2019 Apr;20(4):432-437. doi: 10.1016/j.jamda.2019.01.135.

PMID:
30954133
45.

Association Between Insurance Status and Access to Hospital Care in Emergency Department Disposition.

Venkatesh AK, Chou SC, Li SX, Choi J, Ross JS, D'Onofrio G, Krumholz HM, Dharmarajan K.

JAMA Intern Med. 2019 May 1;179(5):686-693. doi: 10.1001/jamainternmed.2019.0037.

PMID:
30933243
46.

Kept in the dark: Scotland rejects "sunshine" legislation.

Ross JS.

BMJ. 2019 Mar 29;364:l1379. doi: 10.1136/bmj.l1379. No abstract available.

PMID:
30926587
47.

Association of a Risk Evaluation and Mitigation Strategy Program With Transmucosal Fentanyl Prescribing.

Fleischman W, Auth D, Shah ND, Agrawal S, Ross JS.

JAMA Netw Open. 2019 Mar 1;2(3):e191340. doi: 10.1001/jamanetworkopen.2019.1340.

48.

Submissions from the SPRINT Data Analysis Challenge on clinical risk prediction: a cross-sectional evaluation.

Jackevicius CA, An J, Ko DT, Ross JS, Angraal S, Wallach JD, Koh M, Song J, Krumholz HM.

BMJ Open. 2019 Mar 23;9(3):e025936. doi: 10.1136/bmjopen-2018-025936.

49.

U.S. prescribing trends of fentanyl, opioids, and other pain medications in outpatient and emergency department visits from 2006 to 2015.

Vijay A, Rhee TG, Ross JS.

Prev Med. 2019 Jun;123:123-129. doi: 10.1016/j.ypmed.2019.03.022. Epub 2019 Mar 17.

PMID:
30894321
50.

Real-Time Targeted Genome Profile Analysis of Pancreatic Ductal Adenocarcinomas Identifies Genetic Alterations That Might Be Targeted With Existing Drugs or Used as Biomarkers.

Singhi AD, George B, Greenbowe JR, Chung J, Suh J, Maitra A, Klempner SJ, Hendifar A, Milind JM, Golan T, Brand RE, Zureikat AH, Roy S, Schrock AB, Miller VA, Ross JS, Ali SM, Bahary N.

Gastroenterology. 2019 Jun;156(8):2242-2253.e4. doi: 10.1053/j.gastro.2019.02.037. Epub 2019 Mar 2.

Supplemental Content

Support Center